UK regulators said they had identified 30 cases of rare blood clot events related to the AstraZeneca vaccine, but stressed that the benefits of the sting in preventing the coronavirus outweigh the risks.
The Medicines and Healthcare Regulatory Authority (MHRA) said Thursday that the risk associated with this type of blood clot was “very low” and that the public should continue to take the vaccine if it is offered.
The agency said it had identified 30 cases of rare blood clots following the Oxford / AstraZeneca stab out of 18.1 million doses given up to and including March 24th.
Of these, there were reported to have received 22 reports of cerebral venous sinus thrombosis and eight reports of other low platelet thrombosis events.
In response to the data, a member of the Joint Vaccination and Immunization Committee (JCVI) said that including the vaccine was “by far the safest choice” to minimize the risk of serious illness or death.
Professor Adam Finn of the University of Bristol said, “The report says that these cases will be studied very carefully to better understand whether or not they are causally related to vaccination.
“Nevertheless, the extreme rarity of these events in connection with the many millions of vaccine doses administered means that the risk-benefit decision for people invited to take Covid-19 vaccines is very simple: Obtaining the vaccine is far from being the safest choice to minimize the individual risk of serious illness or death. “
Regulators said they had not received any reports of such clotting events after using the Pfizer / BioNTech vaccine.
It comes after Germany is found to have stopped using the AstraZeneca vaccine for people under 60 for fear of an association with rare blood clots.
The head of the European Medicines Agency (EMA) said there was “no evidence” to support a restriction on the use of the AstraZeneca vaccine in a population.
The agency said a causal link between unusual blood clots in people who received the vaccine was “not proven but possible,” adding that the vaccine’s benefits in preventing Covid-19 outweighed the risk of side effects.
This view is borne out by the World Health Organization (WHO), which has urged countries to keep using the push.